Literature DB >> 15650166

An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate.

Jianjiang Ye1, Duane Shedd, George Miller.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) can be driven into the lytic cycle in vitro by phorbol esters and sodium butyrate. This report begins to analyze the process by which butyrate activates the promoter of KSHV open reading frame 50 (ORF50), the key viral regulator of the KSHV latency to lytic cycle switch. A short fragment of the promoter, 134 nucleotides upstream of the translational start of ORF50, retained basal uninduced activity and conferred maximal responsiveness to sodium butyrate. The butyrate response element was mapped to a consensus Sp1-binding site. By means of electrophoretic mobility shift assays, both Sp1 and Sp3 were shown to form complexes in vitro with the ORF50 promoter at the Sp1 site. Butyrate induced the formation of a group of novel complexes, including several Sp3-containing complexes, one Sp1-containing complex, and several other complexes that were not identified with antibodies to Sp1 or Sp3. Formation of all butyrate-induced DNA-protein complexes was mediated by the consensus Sp1 site. In insect and mammalian cell lines, Sp1 significantly activated the ORF50 promoter linked to luciferase. Chromatin immunoprecipitation experiments in a PEL cell line showed that butyrate induced Sp1, CBP, and p300 binding to the ORF50 promoter in vivo in an on-off manner. The results suggest that induction of the KSHV lytic cycle by butyrate is mediated through interactions at the Sp1/Sp3 site located 103 to 112 nucleotides upstream of the translational initiation of ORF50 presumably by enhancing the binding of Sp1 to this site.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650166      PMCID: PMC544116          DOI: 10.1128/JVI.79.3.1397-1408.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  87 in total

1.  Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus.

Authors:  F X Zhu; T Cusano; Y Yuan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

4.  High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations.

Authors:  J C Zong; D M Ciufo; D J Alcendor; X Wan; J Nicholas; P J Browning; P L Rady; S K Tyring; J M Orenstein; C S Rabkin; I J Su; K F Powell; M Croxson; K E Foreman; B J Nickoloff; S Alkan; G S Hayward
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro.

Authors:  K Su; M D Roos; X Yang; I Han; A J Paterson; J E Kudlow
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

6.  Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma.

Authors:  P Monini; S Colombini; M Stürzl; D Goletti; A Cafaro; C Sgadari; S Buttò; M Franco; P Leone; S Fais; P Leone; G Melucci-Vigo; C Chiozzini; F Carlini; G Ascherl; E Cornali; C Zietz; E Ramazzotti; F Ensoli; M Andreoni; P Pezzotti; G Rezza; R Yarchoan; R C Gallo; B Ensoli
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

7.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

Authors:  K A Staskus; W Zhong; K Gebhard; B Herndier; H Wang; R Renne; J Beneke; J Pudney; D J Anderson; D Ganem; A T Haase
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis.

Authors:  A Rickers; N Peters; V Badock; R Beyaert; P Vandenabeele; B Dörken; K Bommert
Journal:  Eur J Biochem       Date:  1999-04

9.  Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells.

Authors:  M Stürzl; C Hohenadl; C Zietz; E Castanos-Velez; A Wunderlich; G Ascherl; P Biberfeld; P Monini; P J Browning; B Ensoli
Journal:  J Natl Cancer Inst       Date:  1999-10-20       Impact factor: 13.506

10.  Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.

Authors:  D M Lukac; J R Kirshner; D Ganem
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

View more
  41 in total

Review 1.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

2.  De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Authors:  Jianjiang Ye; Lyndle Gradoville; Derek Daigle; George Miller
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

3.  Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.

Authors:  Jill K Countryman; Lyndle Gradoville; George Miller
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

Review 4.  Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus replication.

Authors:  Shara N Pantry; Peter G Medveczky
Journal:  Semin Cancer Biol       Date:  2009-02-21       Impact factor: 15.707

5.  The human cytomegalovirus UL112-113 locus can activate the full Kaposi's sarcoma-associated herpesvirus lytic replication cycle.

Authors:  Richard Wells; Laurence Stensland; Jeffrey Vieira
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

6.  ORF45-Mediated Prolonged c-Fos Accumulation Accelerates Viral Transcription during the Late Stage of Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Xiaojuan Li; Shumin Du; Denis Avey; Yuqing Li; Fanxiu Zhu; Ersheng Kuang
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

Review 7.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

8.  Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.

Authors:  Jill Countryman; Lyndle Gradoville; Sumita Bhaduri-McIntosh; Jianjiang Ye; Lee Heston; Sarah Himmelfarb; Duane Shedd; George Miller
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

9.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.